NCT01748669

Brief Summary

Twenty patients of mild to moderate degree of arsenical palmer keratosis will be treated with garlic oil capsule orally for 12 weeks to examine its effectiveness in reducing body arsenic load and clinical symptoms. Similar treatment with similar number of arsenic exposed controls and healthy volunteers will be included for comparison.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
60

participants targeted

Target at P50-P75 for phase_2

Timeline
Completed

Started Oct 2011

Shorter than P25 for phase_2

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

October 1, 2011

Completed
9 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

July 1, 2012

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

July 1, 2012

Completed
5 months until next milestone

First Submitted

Initial submission to the registry

December 11, 2012

Completed
1 day until next milestone

First Posted

Study publicly available on registry

December 12, 2012

Completed
Last Updated

December 12, 2012

Status Verified

December 1, 2012

Enrollment Period

9 months

First QC Date

December 11, 2012

Last Update Submit

December 11, 2012

Conditions

Keywords

ArsenicArsenicosisGarlic oilKeratosis

Outcome Measures

Primary Outcomes (1)

  • Change in the clinical symptom of keratosis in palm

    0 week (baseline) to 12 weeks (end)

Secondary Outcomes (3)

  • Change in biochemical parameters (blood sugar, cholesterol and transaminase) after treatment

    0 week (baseline), 12 weeks (end)

  • Adverse effects following treament

    0 week (baseline), 12 weeks (end)

  • Change in the amount of arsenic in nail

    0 week (baseline), 20 weeks (end)

Study Arms (3)

Patients of palmer arsenical keratosis

EXPERIMENTAL

One soft capsule of garlic oil (10 mg) daily for 12 weeks

Dietary Supplement: Garlic oil

Arsenic exposed controls

ACTIVE COMPARATOR

One soft capsule of garlic oil (10 mg) daily for 12 weeks

Dietary Supplement: Garlic oil

Heathy volunteers

ACTIVE COMPARATOR

One soft capsule of garlic oil (10 mg) daily for 12 weeks

Dietary Supplement: Garlic oil

Interventions

Garlic oilDIETARY_SUPPLEMENT

Oral administration

Arsenic exposed controlsHeathy volunteersPatients of palmer arsenical keratosis

Eligibility Criteria

Age20 Years - 60 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64)

You may qualify if:

  • history of taking arsenic contaminated water (\>50 ppb) for more than 6 months
  • patients having mild to moderate arsenical keratosis present on palm of the hand
  • patients those voluntarily agree to participate
  • family member of the patient
  • drinking arsenic contaminated water from the same source as patient
  • those voluntarily agree to participate
  • no sign/symptom of palmer keratosis
  • drinking arsenic safe water (\<50 ppb)
  • those voluntarily agree to participate

You may not qualify if:

  • pregnancy
  • lactating mother
  • patient receiving treatment of arsenicosis
  • any other chronic disease like tuberculosis, diabetes mellitus, bronchial asthma

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Bangabandhu Sheikh Mujib Medical University

Dhaka, Bangladesh

Location

MeSH Terms

Conditions

Keratosis

Interventions

allyl sulfide

Condition Hierarchy (Ancestors)

Skin DiseasesSkin and Connective Tissue Diseases

Study Officials

  • Mir Misbahuddin, MBBS, PhD

    Department of Pharmacology, Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh.

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
phase 2
Allocation
NON RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Prof. and Chairman, Department of Pharmacology

Study Record Dates

First Submitted

December 11, 2012

First Posted

December 12, 2012

Study Start

October 1, 2011

Primary Completion

July 1, 2012

Study Completion

July 1, 2012

Last Updated

December 12, 2012

Record last verified: 2012-12

Locations